Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

5.1K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
5.1K
Causality in Epidemiology01:21

Causality in Epidemiology

1.6K
Causality or causation is a fundamental concept in epidemiology, vital for understanding the relationships between various factors and health outcomes. Despite its importance, there's no single, universally accepted definition of causality within the discipline. Drawing from a systematic review, causality in epidemiology encompasses several definitions, including production, necessary and sufficient, sufficient-component, counterfactual, and probabilistic models. Each has its strengths and...
1.6K
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

6.5K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.5K
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

9.7K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
9.7K
Common Ion Effect03:24

Common Ion Effect

46.6K
Compared with pure water, the solubility of an ionic compound is less in aqueous solutions containing a common ion (one also produced by dissolution of the ionic compound). This is an example of a phenomenon known as the common ion effect, which is a consequence of the law of mass action that may be explained using Le Châtelier’s principle. Consider the dissolution of silver iodide:
46.6K
Dose Size and Dosing Frequency: Determination Methods01:21

Dose Size and Dosing Frequency: Determination Methods

291
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
291

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same authorSame journal

Current State-of-the-Art and Future Advancements of Model-Based Meta-Analysis.

CPT: pharmacometrics & systems pharmacology·2026
Same author

A Model-Based Meta-Analysis Framework Quantifying Drivers of Placebo Response in Atopic Dermatitis Trials.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Comprehensive Safety Exposure-Response Analysis to Support Ritlecitinib Dose Selection.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Population Pharmacokinetic/Pharmacodynamic and Exposure-Response Modeling of Garadacimab in Healthy Volunteers and Patients With Hereditary Angioedema.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Randomization and placebo effects in clinical trials of major depressive disorder.

Translational psychiatry·2025
Same author

Operating Characteristics of the Simulated Healthy Participant Approach in Impaired Clearance Studies.

The AAPS journal·2025

相关实验视频

Updated: Jan 31, 2026

X-ray Dose Reduction through Adaptive Exposure in Fluoroscopic Imaging
08:30

X-ray Dose Reduction through Adaptive Exposure in Fluoroscopic Imaging

Published on: September 11, 2011

14.9K

一些常见的剂量-暴露-反应估计及其因果识别的条件.

Christian Bartels1, Yuchen Wang2, Jonathan French3

  • 1Novartis Pharma AG, Basel, Switzerland.

CPT: pharmacometrics & systems pharmacology
|January 30, 2026
PubMed
概括

将估计和框架应用于剂量-暴露-反应 (DER) 分析,可以提高药物开发剂量选择. 这种结构化的方法,整合因果推理,提高了DER建模结果的精度和可解释性.

关键词:
有关因果推理的推理.确定剂量的方法.估计和框架 估计和框架暴露 响应 反应药学指标 药学指标 药学指标 药学指标标准化 标准化 标准化

更多相关视频

Long-term Behavioral and Reproductive Consequences of Embryonic Exposure to Low-dose Toxicants
07:08

Long-term Behavioral and Reproductive Consequences of Embryonic Exposure to Low-dose Toxicants

Published on: March 6, 2018

6.7K
A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
05:51

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

Published on: June 15, 2011

26.4K

相关实验视频

Last Updated: Jan 31, 2026

X-ray Dose Reduction through Adaptive Exposure in Fluoroscopic Imaging
08:30

X-ray Dose Reduction through Adaptive Exposure in Fluoroscopic Imaging

Published on: September 11, 2011

14.9K
Long-term Behavioral and Reproductive Consequences of Embryonic Exposure to Low-dose Toxicants
07:08

Long-term Behavioral and Reproductive Consequences of Embryonic Exposure to Low-dose Toxicants

Published on: March 6, 2018

6.7K
A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
05:51

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

Published on: June 15, 2011

26.4K

科学领域:

  • 制药指标 (Pharmacometrics) 是一个指标.
  • 药物开发 药物开发
  • 因果推理因果推理

背景情况:

  • 暴露-反应 (ER) 分析对于药物开发中的剂量选择至关重要.
  • 估计和框架 (ICH E9(R1)) 提供了精确的科学目标定义.
  • 标准ER分析往往缺乏与因果推理原则的正式整合.

研究的目的:

  • 将估计和框架应用于剂量-暴露-反应 (DER) 分析.
  • 通过潜在的结果符号和定向非循环图 (DAG) 形式化剂量反应估计.
  • 为了比较DER估计的不同估计策略.

主要方法:

  • 使用基于真实世界的场景的模拟研究.
  • 估计用潜在结果符号定义和正式化.
  • 定向非循环图 (DAG) 表达了研究假设和关系.
  • 导出了三种估计方法:聚合的DER,聚合的共变量调整的DR和队列总结.

主要成果:

  • 聚合剂量-暴露-反应 (DER) 分析比同变量调整的剂量-反应 (DR) 分析 (较低的平均平方误差) 产生了更精确的估计.
  • 综合方法允许在不同的估计方法中正式评估偏差.
  • 对于相同的估计,不同的估计方法可以进行比较,以验证.

结论:

  • 将估计框架与因果推理整合起来,可以提高DER分析的方法严格性.
  • 这种方法提高了建模假设和结果解释的清晰度.
  • 这种可概括的策略推进了暴露-反应分析,以精确选择剂量,特别是使用多项研究数据.